Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma.

TitleWhole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma.
Publication TypeJournal Article
Year of Publication2016
AuthorsRettig EM, C Talbot C, Sausen M, Jones S, Bishop JA, Wood LD, Tokheim C, Niknafs N, Karchin R, Fertig EJ, Wheelan SJ, Marchionni L, Considine M, Ling S, Fakhry C, Papadopoulos N, Kinzler KW, Vogelstein B, Ha PK, Agrawal N
JournalCancer Prev Res (Phila)
Volume9
Issue4
Pagination265-74
Date Published2016 04
ISSN1940-6215
KeywordsCarcinogenesis, Carcinoma, Adenoid Cystic, Gene Expression Profiling, Gene Rearrangement, Humans, NFI Transcription Factors, Oncogene Proteins, Fusion, Receptors, Notch, RNA, Messenger, Salivary Gland Neoplasms, Sequence Analysis, DNA, Signal Transduction, Translocation, Genetic
Abstract

Adenoid cystic carcinomas (ACC) of the salivary glands are challenging to understand, treat, and cure. To better understand the genetic alterations underlying the pathogenesis of these tumors, we performed comprehensive genome analyses of 25 fresh-frozen tumors, including whole-genome sequencing and expression and pathway analyses. In addition to the well-described MYB-NFIB fusion that was found in 11 tumors (44%), we observed five different rearrangements involving the NFIB transcription factor gene in seven tumors (28%). Taken together, NFIB translocations occurred in 15 of 25 samples (60%, 95% CI, 41%-77%). In addition, mRNA expression analysis of 17 tumors revealed overexpression of NFIB in ACC tumors compared with normal tissues (P = 0.002). There was no difference in NFIB mRNA expression in tumors with NFIB fusions compared with those without. We also report somatic mutations of genes involved in the axonal guidance and Rho family signaling pathways. Finally, we confirm previously described alterations in genes related to chromatin regulation and Notch signaling. Our findings suggest a separate role for NFIB in ACC oncogenesis and highlight important signaling pathways for future functional characterization and potential therapeutic targeting.

DOI10.1158/1940-6207.CAPR-15-0316
Alternate JournalCancer Prev Res (Phila)
PubMed ID26862087
PubMed Central IDPMC4818686
Grant ListR37 CA043460 / CA / NCI NIH HHS / United States
R21 DE023218 / DE / NIDCR NIH HHS / United States
T32 GM007057 / GM / NIGMS NIH HHS / United States
P30 CA006973 / CA / NCI NIH HHS / United States
DE019032 / DE / NIDCR NIH HHS / United States
R01 DE023227 / DE / NIDCR NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
P50 DE019032 / DE / NIDCR NIH HHS / United States
DE023218 / DE / NIDCR NIH HHS / United States
R01-DE023227 / DE / NIDCR NIH HHS / United States
T32 DC000027 / DC / NIDCD NIH HHS / United States
T32 GM008752 / GM / NIGMS NIH HHS / United States
Related Faculty: 
Luigi Marchionni, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700